当前位置: 首页 > 期刊 > 《上海医药》 > 2018年第22期
编号:13284270
癌症抑郁共病的影响因素及药物治疗(3)
http://www.100md.com 2018年8月5日 《上海医药》 2018年第22期
     [15] Li M, Rosenblat J, Rodin G. Management of clinical depression and anxiety[M]. Oxford University Press, 2017, 78-105.

    [16] Miller K, Massie MJ. Depression and anxiety[J]. Cancer J, 2006, 12(5): 388-397.

    [17] Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants[J] .Asia Pac Psychiatry, 2016, 8(3): 179-188.

    [18] Reich M. Depression in oncology[J]. Cancer Radiother, 2010, 14(6-7): 535-538.

    [19] 李力, 郭良君, 李麗莎. 氟西汀治疗癌症抑郁性障碍的临床研究[J]. 实用医学杂志, 2004, 20(7): 823-824.

    [20] Dai J, Liao N, Shi J, et al. Study of prevalence and influencing factors of depression in tumor patients and the therapeutic effects of fluoxetine[J]. Eur Rev Med Pharmacol Sci, 2017, 21(21): 4966-4974.

    [21] Strawn JR, Dobson ET, Giles LL. Primary pediatric care psychopharmacology: Focus on medications for depression, and anxiety[J]. Curr Probl Pediatr Adolesc Health Care, 2017, 47(1): 3-14.

    [22] Perry LM, Hoerger M, Silberstein J, et al. Understanding the distressed prostate cancer patient: Role of personality[J]. Psychooncology, 2018, 27(3): 810-816

    [23] Pranjic N, Bajraktarevic A, Ramic E. Distress and PTSD in patients with cancer: Cohort study case [J]. Mater Sociomed, 2016, 28(1): 12-16., http://www.100md.com(李桂花 任宇 徐峰)
上一页1 2 3